Work

The Use of 5-ALA in Glioblastoma Resection: Two Cases with Long-Term Progression-Free Survival

Year: 2014

Type: article

Abstract: Glioblastoma is the most common and most lethal of all primary brain tumors. Even with the standard triad of surgery, chemotherapy, and radiation therapy, life expectancy is still poor, with a median survival less than 15 months following initial diagnosis. Even though the extent of surgical resection is a prognostic factor affecting outcome, most surgical studies have noted that the complete resection rates are poor due to difficulty in defining the tumor margin intraoperatively. Fluorescence-guided resection (FGR) helps to visualize tumor cells, allowing more complete resection. 5-aminolevulinic acid (5-ALA) in glioma resection has been widely used around the world; however, it is has not been approved in the United States. In this paper, we report two cases of long-term progression-free survival in patients with glioblastoma surgically resected using of 5-ALA.

Source: Cureus

DOI: 10.7759/cureus.202

Authors: Ahmed J Awad, Andrew Sloan

Institution: An-Najah National University

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W2097645937